Fresenius Kabi Awaits EMA Inspection For Pegfilgrastim Biosimilar

Facing Greater Challenge For FDA Approval

 
• By Dean Rudge

Having recently announced plans to launch a further four biosimilar products in the next four years, Fresenius Kabi has disclosed the latest on its bid to introduce pegfilgrastim, which has been hamstrung in the US by delayed inspections.

Start Launch
Fresenius Kabi aims to launch pegfilgrastim in the EU and US next year • Source: Alamy

More from Biosimilars

More from Products